EGFR Mutation Detection for NSCLC Treatment Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for non-small cell lung cancer (NSCLC) have limited effectiveness, with EGFR overexpression leading to chemoresistance and poor prognosis, and existing diagnostic methods fail to accurately identify tumors susceptible to EGFR inhibitors.
Innovation Solution
A method for identifying tumors susceptible to treatment by determining the presence of EGFR mutations in exons 18-21, using nucleic acid probes to detect mutated EGFR proteins, and analyzing the presence of wild-type or mutated KRAS proteins to predict treatment outcomes with EGFR inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy agents are used to treat NSCLC, then some tumor response is achieved, but chemoresistance develops and prognosis remains poor
Solution Approach 1:
The invention changes the therapeutic approach by targeting specific molecular parameters (EGFR mutation status) rather than using conventional chemotherapy. By identifying tumors with EGFR mutations through diagnostic methods, the treatment switches to EGFR inhibitors like erlotinib, which effectively overcome chemoresistance and improve prognosis in mutation-positive patients.
2Reliability
If EGFR inhibitors are used to treat NSCLC, then tumors with EGFR mutations show improved response, but tumors without mutations do not benefit
Solution Approach 1:
The invention applies preliminary diagnostic action to determine EGFR mutation status before initiating EGFR inhibitor therapy. Through methods such as nucleic acid amplification, sequencing, or hybridization assays, the tumor's genetic profile is assessed in advance, ensuring that EGFR inhibitors are prescribed only to patients whose tumors harbor the relevant mutations, thereby maximizing treatment response while avoiding ineffective therapy in mutation-negative patients.
3Measurement precision
If diagnostic methods are expanded to detect all possible tumor mutations, then treatment accuracy improves, but diagnostic complexity and cost increase
Solution Approach 1:
The invention applies local quality by focusing diagnostic efforts on specific, clinically relevant locations within the EGFR gene (exons 18-21, particularly the kinase domain). Rather than screening the entire genome or all exons, the method targets the specific regions where mutations are most likely to confer sensitivity to EGFR inhibitors, thereby achieving high diagnostic precision with reduced complexity and cost.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for better prognosis and treatment outcomes by identifying patients with EGFR mutations in exons 18-21, who exhibit greater response rates and survival benefits when treated with EGFR inhibitors, while also identifying T790M mutations that indicate resistance to these treatments.
Implementation Method 1
using nucleic acid probes to detect hybridization
Implementation Method 2
amplifying nucleic acid corresponding to the kinase domain for electrophoretic mobility comparison
Data Source
AI summary
The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.